Patients with secondary APL are excluded; this includes all patients with APL that may have resulted from prior treatment (chemotherapy or radiation)
Must not have received systemic antineoplastic therapy including radiation therapy within 14 days of the study enrollment, except hydroxyurea or 6-mercaptopurine for the purposes of cytoreduction; patients may also have received all-trans retinoic acid (ATRA) if there is an early suspicion of acute promyelocytic leukemia (acute promyelocytic leukemia [APL], M3-AML), although if confirmed to have APL these patients will be excluded from the study
Subject has a diagnosis of acute promyelocytic leukemia (APL)
COHORT 1: Have histologically or cytologically confirmed relapsed or refractory AML (i.e. >= 5 % blasts by manual differential on bone marrow aspirate / biopsy / flow cytometry), excluding acute promyelocytic leukemia (APL; FAB M3; t [15; 17])
COHORT 2: Have histologically and cytologically confirmed newly diagnosed AML (i.e. >= 20% blasts by manual differential on bone marrow aspirate/biopsy and/or in peripheral blood), excluding acute promyelocytic leukemia (APL; FAB M3, t [15;17])
Documented AML by peripheral blood or bone marrow analyses meeting World Health Organization (WHO) criteria, excluding patients with acute promyelocytic leukemia (APL)
Subject is diagnosed as acute promyelocytic leukemia (APL).
Acute progranulocytic leukemia (APL, M3)
Diagnosed with acute promyelocytic leukemia (APL, M3)
Subject must have confirmation of non-acute promyelocytic leukemia (APL) AML by World Health Organization (WHO) criteria and be ineligible or unwilling to undergo treatment with a standard cytarabine and anthracycline induction regimen due to co-morbidities or other factors
an established, confirmed diagnosis of AML by World Health Organization criteria excluding acute promyelocytic leukemia (APL)-M3; and
Patient with AML according to 2016 WHO criteria (excluding acute promyelocytic leukemia [APL] [AML-M3])
Acute promyelocytic leukemia (APL).
World Health Organization (WHO)-confirmed AML, other than acute promyelocytic leukemia (APL), with no standard treatment options available
Has a diagnosis of acute promyelocytic leukemia (APL) as defined by the World Health Organization
Acute promyelocytic leukemia (APL); patients with brief exposure to all-trans retinoic acid (ATRA), arsenic trioxide (ATO) or similar product for suspected APL, who later turn out not to have APL, are eligible for the study
Diagnosis of acute promyelocytic leukemia (APL M3): t(15;17)(q22;q12); (promyelocytic leukemia [PML]/retinoic acid receptor [RAR] alpha [a]) and variants excluded.
Participants that have acute promyelocytic leukemia (APL).
Acute promyelocytic leukemia (APL, M3 subtype of AML) or patients with a t(9:22) cytogenetic translocation.
Acute promyelocytic leukemia (APL)
Patients must have histologically or cytologically documented newly diagnosed de novo acute myeloid leukemia (non-acute promyelocytic leukemia [APL]) that has not yet been treated; hydrea and all-trans retinoic acid (ATRA) previous treatments are acceptable
Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) PML-RARA
Patients must have histologically confirmed AML or ALL, excluding acute promyelocytic leukemia (APL); for histological confirmation, a bone marrow biopsy and aspirate must be reviewed at Oregon Health & Science University (OHSU)
Diagnosis acute promyelocytic leukemia (APL) with t(15;17)(q22;q12); promyelocytic leukemia-retinoic acid receptor alpha (PML-RARA)
Has a diagnosis of acute promyelocytic leukemia (APL) as defined by the World Health Organization
Acute promyelocytic leukemia (APL, M3) unless failed regimens that included tretinoin, arsenic trioxide, anthracyclines and cytarabine and currently NOT candidates for stem cell transplantation
APL (acute promyelocytic leukemia) by WHO criteria [AML with t(15;17)]
Subjects with acute promyelocytic leukemia (APL)
Acute promyelocytic leukemia (APL)
Have an established, pathologically confirmed diagnoses of AML by World Health Organization (WHO) criteria excluding acute promyelocytic leukemia (APL-M3) with a bone marrow of >5% blasts based on histology or flow cytometry
Diagnosed with acute promyelocytic leukemia (APL, M3)
AML (acute promyelocytic leukemia [APL] excepted) or high-risk MDS (10-19% blasts in marrow by morphology or flow cytometry or blood)
Has acute promyelocytic leukemia (APL, FAB M3).
Diagnosis of acute promyelocytic leukemia (APL, or AML M3 subtype).
Diagnosis of acute myeloid leukemia (AML) by World Health Organization criteria excluding acute promyelocytic leukemia (APL)-M3.
Acute promyelocytic leukemia (APL)
Patients must have histologically or cytologically documented newly diagnosed acute myeloid leukemia (non-acute promyelocytic leukemia [APL]) that has not yet been treated; hydroxyurea (Hydrea) and tretinoin (ATRA) previous treatments are acceptable
Patients with acute promyelocytic leukemia (APL) are not eligible
Acute promyelocytic leukemia (APL)
Patients with acute promyelocytic leukemia (APL) confirmed either by the presence of t(15;17)(q22;q21) or promyelocytic leukemia (PML)/retinoic acid receptor (RAR) alpha transcripts will be excluded
Patients with acute promyelocytic leukemia (APL) as diagnosed by morphologic criteria, flow cytometric characteristics, and rapid cytogenetics or FISH or molecular testing
Patients with newly diagnosed or relapsed/refractory AML, except acute promyelocytic leukemia (APL), requiring intensive induction chemotherapy
AML, other than acute promyelocytic leukemia (APL), in first or second remission or with minimal residual disease
Subject was diagnosed as acute promyelocytic leukemia (APL).
The patient has a diagnosis of AML or BPDCN according to WHO classification (AML; excluding acute promyelocytic leukemia [APL, FAB M3]) or confirmed by hematopathology (BPDCN)
The patient has a diagnosis of AML or BPDCN according to WHO classification (AML; excluding acute promyelocytic leukemia [APL, FAB M3]) or confirmed by hematopathology (BPDCN)
The patient has a diagnosis of acute promyelocytic leukemia (APL; FAB M3).
Diagnosis of acute promyelocytic leukemia (APL)
AML M3 Acute Promyelocytic Leukemia (APL) or patients with a t(9:22) cytogenetic translocation.
Acute promyelocytic leukemia (APL)
Subject was diagnosed as acute promyelocytic leukemia (APL).
Acute promyelocytic leukemia (APL, M3) unless failed regimens that included tretinoin, arsenic trioxide, anthracyclines and cytarabine and currently NOT candidates for stem cell transplantation
Treatment-related AML or acute promyelocytic leukemia (APL)
Acute promyelocytic leukemia (APL)
Diagnosis of acute promyelocytic leukemia (APL)
Cytologically/histologically confirmed acute myeloid leukaemia (AML) according to WHO classification; (except for acute promyelocytic leukaemia (APL).
Patient has acute promyelocytic leukemia (APL).
Confirmed diagnosis of non-acute promyelocytic leukemia (APL) AML (World Health Organization [WHO] criteria)
Acute promyelocytic leukemia (APL)
Newly diagnosed, previously untreated, cytologically/histologically confirmed de novo or secondary AML according to World Health Organization (WHO) classification (except for acute promyelocytic leukemia (APL))
New diagnosis of AML, other than acute promyelocytic leukemia (APL) or poor-risk AML
Acute promyelocytic leukemia (APL, M3)
Acute promyelocytic leukemia (APL)
Patients must have histologically or cytologically confirmed non–acute promyelocytic leukemia (APL) acute myeloid leukemia (AML)
Diagnosis of acute promyelocytic leukemia (APL)
Patients with acute promyelocytic leukemia (APL)
Acute promyelocytic leukemia (APL)
A diagnosis of acute promyelocytic leukemia (APL); the study does not require to rule APL out for every subject; however, if there is clinical suspicion for APL, such diagnosis has to be ruled out before initiation of treatment
Subject was diagnosed as acute promyelocytic leukemia (APL).
World Health Organization (WHO)-confirmed AML, other than acute promyelocytic leukemia (APL)
Diagnosis of acute promyelocytic leukemia (APL).
Acute promyelocytic leukemia (APL)
Patients with the following diagnoses are not eligible:\r\n* Acute promyelocytic leukemia (APL)\r\n* Down syndrome\r\n* Juvenile myelomonocytic leukemia (JMML)
Diagnosis of acute promyelocytic leukemia (APL), French-American-British classification M3 or WHO classification of APL with translocation, t(15;17)(q22;q12), or breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) positive leukemia (ie, chronic myelogenous leukemia in blast crisis); subjects who undergo diagnostic workup for APL and treatment with all-trans retinoic acid (ATRA), but who are found not to have APL, are eligible (treatment with ATRA must be discontinued before starting induction chemotherapy).
Acute promyelocytic leukemia (APL) with PML-RARA
Patients must not have acute promyelocytic leukemia (APL) and must not have evidence of t(15;17)(q22;q21)
Patients with newly diagnosed AML or acute promyelocytic leukemia (APL)
Diagnosis of MDS or AML other than APL with t(15;17)(q22;q12), (promyelocytic leukemia[PML]/retinoic acid receptor [RAR]), or variants according to the 2008 World Health Organization (WHO) classification
Subjects with acute promyelocytic leukemia (APL)